Gilead advances Tecartus case in aggressive blood cancers

Kite, a subsidiary of US biotech major Gilead Sciences (Nasdaq: GILD), has announced the results of new analyses supporting the use of Tecartus (brexucabtagene autoleucel) in relapsed/refractory mantle cell lymphoma (R/R MCL) and relapsed/refractory adult B-cell precursor acute lymphoblastic leukaemia (R/R B-ALL).

These results - presented at the 2023 American Society of Hematology (ASH) Annual Meeting - support the potential long-term response and safety of the CAR T-cell therapy in aggressive blood cancers.

"We are particularly encouraged that the real-world evidence demonstrates consistent outcomes for brexucabtagene autoleucel among a broader range of patients"At a median follow-up of 47.5 months in all 68 patients with R/R MCL who had previously received anthracycline or bendamustine-containing chemotherapy, an anti CD20 antibody, and a Bruton’s tyrosine kinase inhibitor (BTKi, ibrutinib or acalabrutinib), and were treated with brexucabtagene autoleucel in the pivotal ZUMA-2 study, median overall survival was 46.4 months with 44% of patients still alive at data cutoff.